Conor Kilroy Sells 7,162 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Conor Kilroy sold 7,162 shares of the firm’s stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total value of $39,319.38. Following the transaction, the insider now owns 179,313 shares in the company, valued at $984,428.37. This trade represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aura Biosciences Price Performance

Shares of NASDAQ AURA traded down $0.17 during midday trading on Wednesday, hitting $5.40. 138,043 shares of the company’s stock were exchanged, compared to its average volume of 200,409. Aura Biosciences, Inc. has a twelve month low of $3.40 and a twelve month high of $12.38. The firm has a market cap of $271.22 million, a P/E ratio of -3.12 and a beta of 0.43. The stock’s 50 day moving average price is $6.85 and its 200-day moving average price is $8.23.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). On average, analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new stake in shares of Aura Biosciences during the 4th quarter worth about $50,000. GAMMA Investing LLC raised its holdings in Aura Biosciences by 5,766.9% during the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock worth $57,000 after purchasing an additional 9,573 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Aura Biosciences in the fourth quarter worth approximately $87,000. ProShare Advisors LLC acquired a new stake in Aura Biosciences in the fourth quarter worth approximately $127,000. Finally, Harvest Investment Services LLC bought a new position in Aura Biosciences during the 4th quarter valued at $133,000. Institutional investors own 96.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AURA. HC Wainwright set a $25.00 target price on shares of Aura Biosciences in a report on Tuesday, March 25th. JMP Securities set a $19.00 target price on shares of Aura Biosciences in a report on Wednesday, March 26th. Citigroup reiterated an “outperform” rating on shares of Aura Biosciences in a research report on Wednesday, March 26th. Finally, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $22.75.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.